Dermala Scores New Patent Covering the Use of Human Microbiome to Prevent, Slow, and Reverse Skin Aging

The newly patented technology uses novel microbiome formulations and delivery methods to restore biologically "younger" skin and gut microbiomes in older adults.

Dermala has received issuance of a U.S. Patent to use the human microbiome to slow down the skin aging process. 

The newly patented technology uses novel microbiome formulations and delivery methods to restore biologically "younger" skin and gut microbiomes in older adults. This includes transplanting "younger" skin and gut microbiomes or their biosynthetic equivalents and components including prebiotics, probiotics, and postbiotics to older skin.

"Skin aging is associated with changes in skin and gut microbial communities," says Lada Rasochova, Ph.D., MBA, Founder/CEO of Dermala and the patent inventor, in a news release. "Differences between younger and older microbiomes can be striking. Optimizing the microbiome composition by transplanting biologically younger microbiome components onto an aging skin to slow down aging is a novel concept that is poised to revolutionize the skincare industry." 

This patent is a part of an extensive intellectual property portfolio that covers using the skin and gut microbiomes and data analytics to treat various skin diseases and conditions including acne, eczema, and skin aging.